Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)

Inclusion Criteria: * Remission from a major depressive episode after ECT treatment Exclusion Criteria: * Suicidality (Hamilton item 3 score of 3 or more) * Symptoms mania (MAS score of 15 or more) * Duration of actual depressive episode more than 2 years * Compulsory measures of any kind * Dementia * Severe somatic illness * Pregnant or lactating subject * Known clinical relevant malabsorption. * Epilepsia * Clinically substantial cognitive deterioration due to ECT treatment * schizophrenia, schizopreniform or schizo-affective disorder * Bipolar I, Bipolar II eller * Rapid cycling bipolar disorder * Abuse of alcohol or drugs * Early relapse (less than 2 month) after ECT * Inadequate contraception * Known intolerance to any of the used study medications * Myocardial infarction in the last 6 month * Clinical important liver disease * Any known disturbance of the cardiac conduction system, cardiac insufficiency,or other clinical important cardiac disease * Treatment with a MAO-inhibitor * Treatment with norepinephrine or epinephrine * Known hyperthyroidism or treatment with thyroid hormones * Known ortostatic hypertension. * Glaucoma * Known hereditary galactoseintolerance, Lapp Lactase deficiency) or gluco-se/galactosemalabsorption. * Ongoing treatment with sympatomimetica efedrine, isoprenaline, physostigmine, dopamine, levodopa, phenylephrine. * Ongoing treatment with anticholinergica, antiparkinson treatment, antihistamines, atropine, biperiden, * Ongoing treatment with drugs that prolongs the cardiac QT-interval, such as quinidine, antihistamines, terfenadine og sotalole * Ongoing treatment with fluconazole or terbinafine * Ongoing treatment with mefloquin. * Known intolerance to escitalopram * Ongoing treatment with serotonergic acting substances such as tramadole, sumatriptane